肝癌患者肝移植术前使用PD-1抑制剂对移植后排斥反应的影响

崔春晓; 杨柳晓; 王颖; 黄俊峰; 黄晓武; 樊嘉; 周俭; 王婷

doi:10.12025/j.issn.1008-6358.2020.20201005

肝癌患者肝移植术前使用PD-1抑制剂对移植后排斥反应的影响

The effect of PD-1 inhibitor treatment before liver transplantation on posttransplant rejection in liver cancer patients

摘要

摘要:
目的观察肝癌患者肝移植术前使用PD-1抑制剂对肝移植术后排斥反应的影响。
方法选取2019年1月1日至2019年12月31日在复旦大学附属中山医院行肝移植且移植前接受过PD-1抑制剂治疗的肝癌患者，共12例。检测其术后早期他克莫司药物浓度，观察移植术后排斥反应发生情况。
结果术后第1周和第2周他克莫司浓度分别为（5.14±2.68）ng/mL和（8.41±5.73）ng/mL。16.7%（2/12）患者发生细胞性排斥。
结论肝移植术前使用PD-1抑制剂的肝癌患者，其移植术后排斥反应的发生率未见明显增加。

Abstract:
Objective To observe the effect of PD-1 inhibitor treatment before liver transplantation on posttransplant rejection in liver cancer patients.
Methods The data of 12 patients with liver cancer who received PD-1 inhibitor before liver transplantation between January 1 and December 31, 2019 in Zhongshan Hospital, Fudan University were analyzed. The concentration of tacrolimus in the early postoperative period were detected and the occurrence of rejection after transplantation were observed.
Results The tacroliums concentration at 1week or 2 week after liver transplantation were (5.14±2.68) ng/mL and (8.41±5.73) ng/mL. The incidence of rejection after liver transplantation was only 16.7%(2/12).
Conclusion The incidence of rejection after liver transplantation is not significantly increased in patients with liver cancer who use PD-1 inhibitors before liver transplantation.

HTML全文

参考文献(23)

施引文献

资源附件(0)